M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
GSK gains accelerated FDA approval for combination use of MekinistÂ® (trametinib) and TafinlarÂ® (dabrafenib)
London UK USA -- LSE Announcement - First approved combination of oral targeted therapies for unresectable or metastatic melanoma with BRAF V600E or V600K mutations [i]
GlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives